KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Operating Expenses (2018 - 2025)

Historic Operating Expenses for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $89.8 million.

  • Castle Biosciences' Operating Expenses rose 1133.04% to $89.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $378.5 million, marking a year-over-year increase of 2094.72%. This contributed to the annual value of $323.4 million for FY2024, which is 1238.3% up from last year.
  • Castle Biosciences' Operating Expenses amounted to $89.8 million in Q3 2025, which was up 1133.04% from $90.4 million recorded in Q2 2025.
  • Castle Biosciences' Operating Expenses' 5-year high stood at $115.9 million during Q1 2025, with a 5-year trough of $24.1 million in Q1 2021.
  • In the last 5 years, Castle Biosciences' Operating Expenses had a median value of $71.3 million in 2023 and averaged $65.7 million.
  • Per our database at Business Quant, Castle Biosciences' Operating Expenses soared by 13906.92% in 2021 and then skyrocketed by 664.23% in 2024.
  • Over the past 5 years, Castle Biosciences' Operating Expenses (Quarter) stood at $40.2 million in 2021, then soared by 52.13% to $61.2 million in 2022, then increased by 17.34% to $71.8 million in 2023, then grew by 14.6% to $82.3 million in 2024, then rose by 9.22% to $89.8 million in 2025.
  • Its Operating Expenses stands at $89.8 million for Q3 2025, versus $90.4 million for Q2 2025 and $115.9 million for Q1 2025.